NCT01243762 2018-08-16
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)
Merck Sharp & Dohme LLC
Phase 1 Terminated
Clinical Trials
3 trialsNCT00694356 2018-08-08
Study of Dalotuzumab (MK-0646) in Adults With Solid Tumors (MK-0646-009)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00730379 2015-02-10
A Combination Study With Ridaforolimus (MK8669) and Dalotuzumab (MK0646) in Patients With Advanced Cancer (8669-004)
Merck Sharp & Dohme LLC
Phase 1 Completed